Prevalence and predictors of suicidality among adults initiating office-based buprenorphine
Open Access
- 1 June 2023
- journal article
- research article
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 18 (1) , 1-7
Abstract
Background: Individuals who have substance use disorders may have an elevated risk of suicidality. This study sought to examine the prevalence of, and identify factors associated with, suicidality in adults with opioid use disorder (OUD) initiating office-based buprenorphine treatment. Methods: Individuals were eligible to participate if they had OUD and had initiated treatment in the past month. Participants (n = 244) completed a semi-structured interview using the Addiction Severity Index—Lite. Results: At baseline, 37.70% of participants reported significant thoughts of suicide over their lifetime and 27.46% reported suicidal attempts over their lifetime. Logistic regression analyses were used to identify predictors of lifetime suicidal thoughts and attempts. A history of physical abuse (OR = 4.31, p < .001), having chronic pain-related conditions (OR = 3.28, p < .001), a history of depression (OR = 3.30, p = .001) or anxiety (OR = 7.47, p = .001), and Latino/a/x ethnicity (OR = 2.66, p = .01) were associated with an increased risk of lifetime suicidal thoughts. A history of sexual abuse (OR = 2.89, p = .01), Latino/a/x ethnicity (OR = 4.01, p < .001), a history of depression (OR = 4.03, p = .001) or anxiety (OR = 15.65, p = .007) and having a chronic pain-related condition (OR = 2.43, p = .01), were associated with an increased risk of lifetime suicide attempts. Conclusions: Results demonstrate the high prevalence of suicidal thoughts and attempts among patients initiating buprenorphine. Findings may help to better identify at-risk patients and to inform screening, prevention, and mental health treatment efforts. Trial registration: ClinicalTrials.gov, NCT04650386 (registered 12 December 2020, https://clinicaltrials.gov/ct2/show/NCT04650386) and NCT04257214 (registered 5 February 2020, https://clinicaltrials.gov/ct2/show/NCT04257214).Keywords
Funding Information
- Patient-Centered Outcomes Research Institute (OBOT-2018C2-13158)
- Pennsylvania Department of Health (SAP #4100083338)
This publication has 21 references indexed in Scilit:
- Chronic pain and suicide risk: A comprehensive reviewProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2018
- Suicide: A Silent Contributor to Opioid-Overdose DeathsNew England Journal of Medicine, 2018
- Frequency of prescription opioid misuse and suicidal ideation, planning, and attemptsJournal of Psychiatric Research, 2017
- Chronic pain among patients with opioid use disorder: Results from electronic health records dataJournal of Substance Abuse Treatment, 2017
- Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health AdministrationAddiction, 2017
- Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled TrialAmerican Journal of Psychiatry, 2016
- Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives savedDrug and Alcohol Dependence, 2009
- Cross-national prevalence and risk factors for suicidal ideation, plans and attemptsThe British Journal of Psychiatry, 2008
- Childhood Sexual and Physical Abuse and Adult Self-Harm and Suicidal Behaviour: A Literature ReviewThe Canadian Journal of Psychiatry, 1998
- The prediction of suicide.1990